Previous studies indicate that the presence of angiogenic factors is a necessary event in the progression of PM [8–10] Moreover it was reported that vascular endothelial growth factor (VEGF) is associated with PM in GC and that VEGF is a significant indicator of peritoneal recurrence [11, 12] Bevacizumab, a monoclonal antibody that recognizes the VEGF-A isoform, inhibits tumor growth by blocking angiogenesis. The gene discussed is VEGFA; the disease is gastric cancer.